Coverage
Filings
Swedish Orphan Biovitrum AB on Monday reported a 21% rise in third-quarter revenue at constant currencies, but a significant writedown on its cancer drug Vonjo pushed the company to a net loss.
Swedish Orphan Biovitrum AB raised its full-year 2025 forecast on Sunday, citing strong third-quarter sales, while also announcing a significant non-cash impairment charge related to its drug Vonjo.
Swedish Orphan Biovitrum AB on Wednesday reported a 13% rise in second-quarter revenue, driven by strong sales in its haematology drug portfolio.
Swedish Orphan Biovitrum AB will pay partner Apellis Pharmaceuticals $275 million upfront to amend a royalty agreement for the rare disease drug Aspaveli, the company said Tuesday.
Swedish Orphan Biovitrum AB has won expanded U.S. Food and Drug Administration approval for its drug Gamifant to treat a rare and life-threatening inflammatory complication associated with Still's disease.
| 15 Jul 2025 |
| Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) | 1 Jul 2025 |
| FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease | 28 Jun 2025 |
| Bulletin from Sobi's Annual General Meeting (AGM) | 8 May 2025 |
| Sobi publishes Q1 2025 report: Portfolio continues to deliver | 29 Apr 2025 |